Apimeds Pharmaceuticals US (APUS) Market Capitalization (2025 - 2026)
Apimeds Pharmaceuticals US's (APUS) quarterly Market Capitalization came in at $1.4 million in Q2 2026, down 92.56% on a YoY basis from $18.2 million in Q2 2025, and down 93.41% quarter-over-quarter from $20.6 million in Q4 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Market Capitalization (2025 - 2026) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Market Capitalization for 2 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Market Capitalization fell 92.56% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (down 92.56% YoY), and the FY2025 full-year result was $20.6 million, changed N/A from the prior year.
- Market Capitalization fell to $1.4 million in Q2 2026 per APUS's latest filing, from $20.6 million in the prior quarter.
- Across five years, Market Capitalization topped out at $22.4 million in Q3 2025 and bottomed at $1.4 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Dec 31, 2025 | 20.62 Mn |
| Sep 30, 2025 | 22.39 Mn |
| Jun 30, 2025 | 18.25 Mn |